Blanche P Alter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1657277/publications.pdf

Version: 2024-02-01

207 papers

11,819 citations

28274 55 h-index 30087 103 g-index

211 all docs

211 docs citations

times ranked

211

9575 citing authors

#	Article	IF	CITATIONS
1	Pathophysiology and management of inherited bone marrow failure syndromes. Blood Reviews, 2010, 24, 101-122.	5.7	432
2	Cancer incidence in persons with Fanconi anemia. Blood, 2003, 101, 822-826.	1.4	430
3	Cancer in dyskeratosis congenita. Blood, 2009, 113, 6549-6557.	1.4	413
4	Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. British Journal of Haematology, 2008, 142, 859-876.	2.5	408
5	The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood, 2006, 107, 4628-4635.	1.4	394
6	Cancer in Fanconi anemia, 1927–2001. Cancer, 2003, 97, 425-440.	4.1	387
7	TINF2, a Component of the Shelterin Telomere Protection Complex, Is Mutated in Dyskeratosis Congenita. American Journal of Human Genetics, 2008, 82, 501-509.	6.2	368
8	Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood, 2007, 110, 1439-1447.	1.4	296
9	Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25.	6.3	295
10	Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. British Journal of Haematology, 2010, 150, 179-188.	2.5	272
11	Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood, 2012, 119, 3815-3819.	1.4	263
12	Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood, 2005, 105, 67-73.	1.4	244
13	Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica, 2018, 103, 30-39.	3.5	236
14	Fanconi's anemia and malignancies. American Journal of Hematology, 1996, 53, 99-110.	4.1	225
15	Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature, 2011, 474, 399-402.	27.8	220
16	Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. Journal of Medical Genetics, 2006, 44, 1-9.	3.2	215
17	Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes and Development, 2011, 25, 11-16.	5.9	213
18	Stable longâ€term risk of leukaemia in patients with severe congenital neutropenia maintained on Gâ€CSF therapy. British Journal of Haematology, 2010, 150, 196-199.	2.5	211

#	Article	IF	CITATIONS
19	Androgens and liver tumors: Fanconi's anemia and nonâ€Fanconi's conditions. American Journal of Hematology, 2004, 77, 257-267.	4.1	207
20	Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Human Genetics, 2013, 132, 473-480.	3.8	198
21	Dyskeratosis Congenita. Hematology/Oncology Clinics of North America, 2009, 23, 215-231.	2.2	195
22	Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica, 2012, 97, 353-359.	3.5	194
23	Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica, 2008, 93, 511-517.	3.5	182
24	Fanconi Anemia. Seminars in Hematology, 2006, 43, 147-156.	3.4	174
25	Diagnosis, Genetics, and Management of Inherited Bone Marrow Failure Syndromes. Hematology American Society of Hematology Education Program, 2007, 2007, 29-39.	2.5	174
26	Fanconi anemia and the development ofÂleukemia. Best Practice and Research in Clinical Haematology, 2014, 27, 214-221.	1.7	166
27	Comparative genome analysis delimits a chromosomal domain and identifies key regulatory elements in the alpha globin cluster. Human Molecular Genetics, 2001, 10, 371-382.	2.9	151
28	Cancer in Fanconi anemia. Blood, 2003, 101, 2072-2072.	1.4	147
28	Cancer in Fanconi anemia. Blood, 2003, 101, 2072-2072. Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631.	1.4 3.6	147 120
	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and		
29	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow	3.6	120
30	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging, 2010, 2, 867-874. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Reviews, 2019, 37,	3.6	120
29 30 31	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging, 2010, 2, 867-874. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Reviews, 2019, 37, 100589. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita.	3.6 3.1 5.7	120 120 116
29 30 31 32	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging, 2010, 2, 867-874. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Reviews, 2019, 37, 100589. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2013, 19, 1238-1243. A Recessive Founder Mutation in Regulator of Telomere Elongation Helicase 1, RTEL1, Underlies Severe	3.6 3.1 5.7 2.0	120 120 116 108
29 30 31 32 33	Endocrine Abnormalities in Patients with Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2624-2631. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging, 2010, 2, 867-874. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Reviews, 2019, 37, 100589. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2013, 19, 1238-1243. A Recessive Founder Mutation in Regulator of Telomere Elongation Helicase 1, RTEL1, Underlies Severe Immunodeficiency and Features of Hoyeraal Hreidarsson Syndrome. PLoS Genetics, 2013, 9, e1003695. Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere	3.6 3.1 5.7 2.0	120 120 116 108

#	Article	IF	Citations
37	How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. American Journal of Medical Genetics, Part A, 2011, 155, 1877-1883.	1.2	95
38	Response to androgen therapy in patients with dyskeratosis congenita. British Journal of Haematology, 2014, 165, 349-357.	2.5	89
39	Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Science Translational Medicine, 2017, 9, .	12.4	87
40	Individualized risks of first adverse events in patients with Fanconi anemia. Blood, 2004, 104, 350-355.	1.4	84
41	Dyskeratosis Congenita. Journal of Pediatric Hematology/Oncology, 1992, 14, 297-304.	0.6	82
42	Shwachman-Diamond syndrome: Report from an international conference. Journal of Pediatrics, 2002, 141, 266-270.	1.8	81
43	Whole-exome sequencing and functional studies identify RPS29 as a novel gene mutated in multicase Diamond-Blackfan anemia families. Blood, 2014, 124, 24-32.	1.4	79
44	Fanconi's anaemia and pregnancy. British Journal of Haematology, 1991, 77, 410-418.	2.5	78
45	Erythrocyte adenosine deaminase: diagnostic value for Diamondâ€Blackfan anaemia. British Journal of Haematology, 2013, 160, 547-554.	2.5	76
46	Endocrine Disorders in Fanconi Anemia: Recommendations for Screening and Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 803-811.	3.6	76
47	Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2020, 7, e238-e246.	4.6	73
48	Ocular and Orbital Manifestations of the Inherited Bone Marrow Failure Syndromes: Fanconi Anemia and Dyskeratosis Congenita. Ophthalmology, 2010, 117, 615-622.	5.2	72
49	Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation. Journal of Medical Genetics, 2017, 54, 417-425.	3.2	71
50	Dyskeratosis congenita: The first NIH clinical research workshop. Pediatric Blood and Cancer, 2009, 53, 520-523.	1.5	66
51	The role of telomere biology in bone marrow failure and other disorders. Mechanisms of Ageing and Development, 2008, 129, 35-47.	4.6	64
52	Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia. Blood, 2018, 132, 2205-2208.	1.4	64
53	Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: A search for human papillomavirus. International Journal of Cancer, 2013, 133, 1513-1515.	5.1	63
54	Telomere length in inherited bone marrow failure syndromes. Haematologica, 2015, 100, 49-54.	3.5	63

#	Article	IF	CITATIONS
55	Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry. Haematologica, 2010, 95, 1300-1307.	3.5	57
56	Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood, 2017, 130, 2257-2264.	1.4	57
57	Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case Report and systematic literature review. BMC Blood Disorders, 2011, 11, 3.	0.9	56
58	Fanconi Anemia. JAMA Otolaryngology, 2005, 131, 635.	1.2	55
59	Bone marrow failure syndromes in children. Pediatric Clinics of North America, 2002, 49, 973-988.	1.8	54
60	A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell–based assay. Blood, 2011, 118, 2430-2442.	1.4	53
61	p53 Protein Overexpression in Bone Marrow Biopsies of Patients With Shwachman-Diamond Syndrome Has a Prevalence Similar to That of Patients With Refractory Anemia. Archives of Pathology and Laboratory Medicine, 2002, 126, 452-455.	2.5	51
62	Comparison of Chromosome Breakage in Non-Mosaic and Mosaic Patients with Fanconi Anemia, Relatives, and Patients with Other Inherited Bone Marrow Failure Syndromes. Cytogenetic and Genome Research, 2014, 144, 15-27.	1.1	47
63	Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis, 2019, 22, 95-102.	7.2	45
64	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biology of Blood and Marrow Transplantation, 2017, 23, 1422-1428.	2.0	43
65	Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colonyâ€stimulating factor. British Journal of Haematology, 2007, 138, 815-817.	2.5	42
66	Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives. International Journal of Molecular Sciences, 2017, 18, 1765.	4.1	42
67	Reâ€equilibration of imbalanced NAD metabolism ameliorates the impact of telomere dysfunction. EMBO Journal, 2020, 39, e103420.	7.8	42
68	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. European Respiratory Journal, 2017, 49, 1601640.	6.7	41
69	Fanconi's Anemia, transplantation, and cancer. Pediatric Transplantation, 2005, 9, 81-86.	1.0	38
70	Thinking of VACTERLâ€H? Rule out Fanconi Anemia according to PHENOS. American Journal of Medical Genetics, Part A, 2016, 170, 1520-1524.	1.2	38
71	Clonal chromosomal abnormalities in Fanconi's anaemia: what do they really mean?. British Journal of Haematology, 1993, 85, 627-630.	2.5	36
72	Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Hematology American Society of Hematology Education Program, 2017, 2017, 88-95.	2.5	36

#	Article	IF	CITATIONS
73	JUVENILE CHRONIC MYELOGENOUS LEUKAEMIA: THE ONLY EXAMPLE OF TRULY FETAL (NOT FETAL-LIKE) ERYTHROPOIESIS. British Journal of Haematology, 1990, 76, 307-310.	2.5	35
74	Immune status of patients with inherited bone marrow failure syndromes. American Journal of Hematology, 2015, 90, 702-708.	4.1	34
75	Disease progression and clinical outcomes in telomere biology disorders. Blood, 2022, 139, 1807-1819.	1.4	34
76	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2017, 23, 24-29.	2.0	33
77	Intensive Immunosuppression Therapy for Aplastic Anemia Associated with Dyskeratosis Congenita. International Journal of Hematology, 2006, 83, 275-276.	1.6	32
78	Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. Blood, 2015, 125, 793-802.	1.4	31
79	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation,	2.0	31
80	Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatric Blood and Cancer, 2012, 59, 922-924.	1.5	30
81	Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Advances, 2018, 2, 1243-1249.	5.2	30
82	Treatment of dyskeratosis congenita with Granulocyte Colonyâ€Stimulating Factor and Erythropoietin. British Journal of Haematology, 1997, 97, 309-311.	2.5	29
83	Sources of Uncertainty and Their Association with Medical Decision Making: Exploring Mechanisms in Fanconi Anemia. Annals of Behavioral Medicine, 2013, 46, 204-216.	2.9	29
84	Dubowitz Syndrome Is a Complex Comprised of Multiple, Genetically Distinct and Phenotypically Overlapping Disorders. PLoS ONE, 2014, 9, e98686.	2.5	29
85	Anti-Mýllerian Hormone Deficiency in Females With Fanconi Anemia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1608-1614.	3.6	29
86	Hoyeraal-Hreidarsson Syndrome due to PARN Mutations: Fourteen Years of Follow-Up. Pediatric Neurology, 2016, 56, 62-68.e1.	2.1	29
87	The relationship between DNA methylation and telomere length in dyskeratosis congenita. Aging Cell, 2012, 11, 24-28.	6.7	28
88	Globin Chain Electrophoresis for Prenatal Diagnosis of β Thalassemia. Hemoglobin, 1981, 5, 357-370.	0.8	27
89	Erythropoiesis is Distinct at Each Stage of Ontogeny. Pediatric Research, 1992, 31, 170-175.	2.3	27
90	CURRENT DIAGNOSIS OF INHERITED BONE MARROW FAILURE SYNDROMES. Pediatric Hematology and Oncology, 2007, 24, 87-99.	0.8	27

#	Article	IF	CITATIONS
91	Pregnancy in bone marrow failure syndromes: Diamond-Blackfan anaemia and Shwachman-Diamond syndrome. British Journal of Haematology, 1999, 107, 49-54.	2.5	26
92	The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita. Human Molecular Genetics, 2012, 21, 721-729.	2.9	26
93	Neuropsychiatric Conditions Among Patients with Dyskeratosis Congenita: A Link with Telomere Biology?. Psychosomatics, 2012, 53, 230-235.	2.5	26
94	Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. Science Translational Medicine, 2020, 12, .	12.4	26
95	Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells, Molecules, and Diseases, 2006, 37, 134-136.	1.4	25
96	Novel <i>FANCI</i> mutations in Fanconi anemia with VACTERL association. American Journal of Medical Genetics, Part A, 2016, 170, 386-391.	1.2	25
97	Germline mutation of <i>MDM4</i> , a major p53 regulator, in a familial syndrome of defective telomere maintenance. Science Advances, 2020, 6, eaay3511.	10.3	25
98	Research participant interest in primary, secondary, and incidental genomic findings. Genetics in Medicine, 2016, 18, 1218-1225.	2.4	24
99	Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. Journal of the American Academy of Dermatology, 2018, 78, 804-806.	1.2	23
100	Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1888-1892.	2.0	22
101	Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. American Journal of Hematology, 2016, 91, 1215-1220.	4.1	22
102	Genetic regulation of fetal haemoglobin in inherited bone marrow failure syndromes. British Journal of Haematology, 2013, 162, 542-546.	2.5	21
103	The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. Molecular Genetics & Congenita Medicine, 2016, 4, 475-479.	1.2	20
104	CNS manifestations in patients with telomere biology disorders. Neurology: Genetics, 2019, 5, 370.	1.9	17
105	Aplastic Anemia, Pediatric Aspects. Oncologist, 1996, 1, 361-366.	3.7	16
106	Bone Marrow Failure: A Child Is Not Just a Small Adult (But an Adult Can Have a Childhood Disease). Hematology American Society of Hematology Education Program, 2005, 2005, 96-103.	2.5	16
107	Bone marrow cell cycle markers in inherited bone marrow failure syndromes. Leukemia Research, 2008, 32, 1793-1799.	0.8	15
108	PROLIFERATIVE RETINOPATHY AS A COMPLICATION OF DYSKERATOSIS CONGENITA. Retinal Cases and Brief Reports, 2009, 3, 259-262.	0.6	15

#	Article	IF	Citations
109	Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes. British Journal of Haematology, 2013, 163, 81-92.	2.5	15
110	Genetic Informationâ€Seeking Behaviors and Knowledge among Family Members and Patients with Inherited Bone Marrow Failure Syndromes. Journal of Genetic Counseling, 2015, 24, 760-770.	1.6	15
111	Pregnancies in patients with inherited bone marrow failure syndromes in the NCI cohort. Blood, 2017, 130, 1674-1676.	1.4	15
112	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	8.2	15
113	Reduced Serum Levels of Anti-Mþllerian Hormone in Females With Inherited Bone Marrow Failure Syndromes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E197-E203.	3.6	14
114	Preemptive Bone Marrow Transplantation for FANCD1/BRCA2. Biology of Blood and Marrow Transplantation, 2015, 21, 1796-1801.	2.0	14
115	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
116	Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. Journal of Pediatrics, 2021, 230, 55-61.e4.	1.8	14
117	PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES: THE NEW ENGLAND APPROACH. Annals of the New York Academy of Sciences, 1980, 344, 151-164.	3.8	13
118	Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. Vaccine, 2014, 32, 1169-1173.	3.8	13
119	Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder. ERJ Open Research, 2019, 5, 00209-2019.	2.6	13
120	Expansion of germline <i>RPS20</i> mutation phenotype to include Diamond–Blackfan anemia. Human Mutation, 2020, 41, 1918-1930.	2.5	13
121	The effect of hemin in vitro and in vivo on human erythroid progenitor cells. International Journal of Cell Cloning, 1986, 4, 432-446.	1.6	12
122	Prenatal Diagnosis of Hemoglobinopathies: A Potential Application of High Performance Liquid Chromatography. Hemoglobin, 1987, 11, 341-352.	0.8	12
123	Sickle and Thalassemic Erythroid Progenitor Cells are Different from Normal. Hemoglobin, 1992, 16, 447-467.	0.8	12
124	The association between FANCD1/BRCA2 mutations and leukaemia British Journal of Haematology, 2006, 133, 446-448.	2.5	12
125	Sequence analysis of the shelterin telomere protection complex genes in dyskeratosis congenita. Journal of Medical Genetics, 2011, 48, 285-288.	3.2	12
126	Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leukemia Research, 2012, 36, 29-31.	0.8	12

#	Article	IF	Citations
127	Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in <i>RPL35A</i> . Haematologica, 2021, 106, 1303-1310.	3.5	12
128	Pregnancy outcomes in mothers of offspring with inherited bone marrow failure syndromes. Pediatric Blood and Cancer, 2018, 65, e26757.	1.5	11
129	Prenatal Diagnosis: General Introduction, Methodology, and Review. Hemoglobin, 1988, 12, 763-772.	0.8	10
130	Otologic manifestations of Fanconi anemia and other inherited bone marrow failure syndromes. Pediatric Blood and Cancer, 2016, 63, 2139-2145.	1.5	10
131	Bone mineral density in patients with inherited bone marrow failure syndromes. Pediatric Research, 2017, 82, 458-464.	2.3	10
132	Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. Haematologica, 2023, 108, 69-82.	3.5	10
133	All in the family: Disclosure of "unwanted―information to an adolescent to benefit a relative. American Journal of Medical Genetics, Part A, 2008, 146A, 2719-2724.	1.2	9
134	Pearson syndrome in a Diamond-Blackfan anemia cohort. Blood, 2014, 124, 312-313.	1.4	9
135	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
136	Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2003-2008.	2.0	9
137	Progressive reticulate skin pigmentation and anonychia in a patient with bone marrow failure. Journal of the American Academy of Dermatology, 2017, 77, 1194-1198.	1.2	8
138	Neutrophil functions in patients with inherited bone marrow failure syndromes. Pediatric Blood and Cancer, 2011, 57, 306-309.	1.5	7
139	The use of haematopoietic stem cell transplantation in Fanconi anaemia patients: a survey of decision making among families in the US and Canada. Health Expectations, 2015, 18, 929-941.	2.6	7
140	Complex phenotype of dyskeratosis congenita and mood dysregulation with novel homozygous <i>RTEL1</i> and <i>TPH1</i> variants. American Journal of Medical Genetics, Part A, 2018, 176, 1432-1437.	1.2	7
141	Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2). Cancer Genetics, 2021, 258-259, 101-109.	0.4	7
142	Lack of effect of corticosteroids in W/W ^v and Sl/Sl ^d mice: These strains are not a model for steroidâ€responsive Diamondâ€Blackfan anemia. European Journal of Haematology, 1993, 50, 275-278.	2.2	6
143	Population Frequency of Fanconi Pathway Gene Variants and Their Association with Survival After Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 817-822.	2.0	6
144	Bone marrow transplantation in two multiply transfused patients with thalassaemia major. British Journal of Haematology, 1986, 63, 445-456.	2.5	5

#	Article	IF	Citations
145	The CCC System: Is It Really the Answer to Pediatric MDS?. Journal of Pediatric Hematology/Oncology, 2003, 25, 426-427.	0.6	5
146	Growth hormone and the risk of malignancy. Pediatric Blood and Cancer, 2004, 43, 534-535.	1.5	5
147	Wilms tumor, AML, and medulloblastoma in a child with cancer prone syndrome of total premature chromatid separation and Fanconi anemia. Pediatric Blood and Cancer, 2010, 54, 488-488.	1.5	5
148	Gynaecological and reproductive health of women with telomere biology disorders. British Journal of Haematology, 2021, 193, 1238-1246.	2.5	5
149	Pathogenic germline <i>IKZF1</i> variant alters hematopoietic gene expression profiles. Journal of Physical Education and Sports Management, 2021, 7, a006015.	1.2	5
150	Fanconi's anemia and malignancies. American Journal of Hematology, 1996, 53, 99-110.	4.1	5
151	Risk of cancer in heterozygous relatives of patients with Fanconi anemia. Genetics in Medicine, 2022, 24, 245-250.	2.4	5
152	Shwachman Diamond syndrome: narrow genotypic spectrum and variable clinical features. Pediatric Research, 2022, , .	2.3	5
153	Bone marrow failure syndromes., 0,, 47-64.		4
154	1q21.1 deletion and a rare functional polymorphism in siblings with thrombocytopenia-absent radius–like phenotypes. Journal of Physical Education and Sports Management, 2019, 5, a004564.	1.2	4
155	Correlation of Telomere Length in Blood, Buccal Cells, and Fibroblasts From Patients with Inherited Bone Marrow Failure Syndromes Blood, 2009, 114, 1083-1083.	1.4	4
156	Successful treatment of diamond-blackfan anemia with interleukin 3. Stem Cells, 1996, 11, 123-130.	3.2	3
157	Dyskeratosis congenita: Nails and hands. , 1998, 58, 298-298.		3
158	In reference to <i>Natural history and management of fanconi anemia patients with head and neck cancer: A 10â€year followâ€up</i> . Laryngoscope, 2016, 126, E229.	2.0	3
159	Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2020, 182, 465-476.	2.5	3
160	Phenotypes of Diamond Blackfan Anemia Patients with RPL35A Haploinsufficiency Due to 3q29 Deletion Compared with RPL35A Single Nucleotide Variants or Small Insertion/Deletions. Blood, 2018, 132, 3854-3854.	1.4	3
161	How Rare Is Rare? Carrier Frequencies for Fanconi Anemia In the United States and Israel. Blood, 2010, 116, 2229-2229.	1.4	3
162	The incidence and spectrum of congenital hand differences in patients with Fanconi anaemia: analysis of 48 patients. Journal of Hand Surgery: European Volume, 2022, 47, 711-715.	1.0	3

#	Article	IF	CITATIONS
163	The effect of hemin in vitro and in vivo on human erythroid progenitor cells. International Journal of Cell Cloning, 1986, 4, 432-446.	1.6	2
164	Thrombocytopenia, multiple mucosal squamous cell carcinomas, and dyspigmentation. Journal of the American Academy of Dermatology, 2006, 54, 1056-1059.	1.2	2
165	Heritable cancer: Rounding up the not so usual suspects. Pediatric Blood and Cancer, 2017, 64, 219-220.	1.5	2
166	The causes of Fanconi anemia in South Asia and the Middle East: A case series and review of the literature. Molecular Genetics & Eamp; Genomic Medicine, 2021, 9, e1693.	1.2	2
167	Large Genomic Deletions in Shwachman-Diamond Syndrome. Blood, 2018, 132, 2586-2586.	1.4	2
168	The Incidence of Leukemia and Mortality from Sepsis in Patients with Severe Congenital Neutropenia Receiving Long-Term G-CSF Therapy Blood, 2005, 106, 669-669.	1.4	2
169	Cancer Epidemiology in the National Cancer Institute Inherited Bone Marrow Failure Syndromes Cohort: First Report. Blood, 2008, 112, 40-40.	1.4	2
170	Stable Long-Term Risk of Leukemia in Patients with Severe Congenital Neutropenia Maintained On G-CSF Therapy Blood, 2009, 114, 3206-3206.	1.4	2
171	Cancer in the National Cancer Institute Inherited Bone Marrow Failure Syndrome Cohort after 15 Years of Follow-up. Blood, 2016, 128, 334-334.	1.4	2
172	Myelodysplasia, Leukemia, Lymphoid Malignancies, and Other Cancers in Patients with Severe Chronic Neutropenia. Blood, 2018, 132, 16-16.	1.4	2
173	Genotype-Phenotype Associations in Patients with Fanconi Anemia: National Cancer Institute Cohort. Blood, 2020, 136, 4-5.	1.4	2
174	Fanconi anaemia: A syndrome with distinct subgroups. British Journal of Haematology, 2022, 197, 467-474.	2.5	2
175	Fanconi anemia in blacks. American Journal of Medical Genetics Part A, 1992, 42, 393-393.	2.4	1
176	Modulation of macrocytosis in aplastic anemia. , 1998, 57, 92-92.		1
177	Comment on: "The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes". Haematologica, 2015, 100, e378-e378.	3.5	1
178	Serum alpha fetoprotein levels in Fanconi anaemia. British Journal of Haematology, 2019, 184, 1074-1076.	2.5	1
179	Response to Androgen Therapy and Side Effects in Patients with Dyskeratosis Congenita Blood, 2012, 120, 2361-2361.	1.4	1
180	Impact of G-CSF on Outcomes of Pregnancy in Women with Severe Chronic Neutropenia. Blood, 2011, 118, 4786-4786.	1.4	1

#	Article	lF	CITATIONS
181	Novel Fanci Mutations in Fanconi Anemia with Vacterl Association. Blood, 2015, 126, 4780-4780.	1.4	1
182	Cancer in Heterozygote Carriers of Fanconi Anemia Genes. Blood, 2018, 132, 3868-3868.	1.4	1
183	Genomic-Based Machine Learning Towards Prediction of the Etiology of Bone Marrow Failure Syndromes. Blood, 2021, 138, 2182-2182.	1.4	1
184	Lipoprotein particle alterations due to androgen therapy in individuals with dyskeratosis congenita. EBioMedicine, 2022, 75, 103760.	6.1	1
185	HAEMOGLOBIN SYNTHESIS IN ERYTHROID CULTURE. British Journal of Haematology, 1982, 51, 661-662.	2.5	0
186	FANCONI'S ANAEMIA AND ITS VARIABILITY. British Journal of Haematology, 1994, 86, 895-896.	2.5	0
187	Clinical features and diagnosis of Fanconi's anemia. , 1999, , 319-337.		0
188	Modern Review of Congenital Hypoplastic Anemia. The American Journal of Pediatric Hematology/oncology, 2001, 23, 383-384.	1.3	0
189	Pituitary abnormalities in patients with Fanconi anaemia. Clinical Endocrinology, 2016, 84, 307-309.	2.4	0
190	Cancer-Prone Inherited Bone Marrow Failure, Myelodysplastic, and Acute Myeloid Leukemia Syndromes., 2021,, 267-314.		0
191	Cancer as the Initial Presentation in Patients with Fanconi's Anemia Blood, 2005, 106, 3745-3745.	1.4	0
192	Cyclic Neutropenia Is Not Associated with Transformation to MDS and AML. Blood, 2007, 110, 3306-3306.	1.4	0
193	Central Nervous System Abnormalities in Dyskeratosis Congenita and Fanconi Anemia: Correlation with Clinical Phenotype and Aplastic Anemia Blood, 2007, 110, 1682-1682.	1.4	О
194	Predictors of Transformation to Myelodysplasia/Acute Myelogenous Leukemia (MDS/AML) in Severe Congenital Neutropenia (SCN) Blood, 2007, 110, 3307-3307.	1.4	0
195	Risk for Septic Death in Severe Congenital Neutropenia. Blood, 2008, 112, 3548-3548.	1.4	0
196	Israeli Fanconi Anemia Registry. Blood, 2008, 112, 4125-4125.	1.4	0
197	Very Short Telomeres Are Characteristic of Dyskeratosis Congenita and Not Other Inherited Bone Marrow Failure Syndromes. Blood, 2008, 112, 1044-1044.	1.4	0
198	Frequency and Natural History of Inherited Bone Marrow Failure Syndromes: The Israeli Inherited Bone Marrow Failure Registry. Blood, 2008, 112, 1045-1045.	1.4	0

#	Article	IF	CITATIONS
199	The First Single Center Phenotypic Comparison of Fanconi Anemia, Dyskeratosis Congenita, Diamond-Blackfan Anemia, and Shwachman- Diamond Syndrome: The NCI IBMFS Cohort Blood, 2008, 112, 2043-2043.	1.4	0
200	Stem Cell Transplantation for Fanconi Anemia: A Survey of Decision-Making among Families in the US and Canada Blood, 2009, 114, 3207-3207.	1.4	0
201	Diagnosis of Fanconi Anemia in An Asymptomatic Adult with Mosaicism and a Molecular Explanation Blood, 2009, 114, 4213-4213.	1.4	0
202	Immunosuppressive Therapy and Future Response to Androgens or Survival After Hematopoietic Stem Cell Transplantation in Fanconi Anemia Blood, 2009, 114, 1082-1082.	1.4	0
203	Bone Marrow Fibrosis in Patients with Inherited Bone Marrow Failure Syndromes Blood, 2009, 114, 3192-3192.	1.4	O
204	Bone Marrow Cellular Composition and Inflammatory Cytokine Expression in Patients with Inherited Bone Marrow Failure Syndromes. Blood, 2012, 120, 4401-4401.	1.4	0
205	Germline Mutations in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia. Blood, 2016, 128, 68-68.	1.4	O
206	<i>FANCA</i> Variants in Exons 27-30 Are Associated with Solid Tumors in Fanconi Anemia. Blood, 2021, 138, 2192-2192.	1.4	0
207	Disease Progression and Outcomes in Patients with Telomere Biology Disorders. Blood, 2020, 136, 19-20.	1.4	O